Key result
After 25 years, 72% of Nipah virus survivors from the 1998 Malaysia outbreak retained detectable neutralizing antibodies and demonstrated memory B cell responses.
Why the study?
To evaluate the long-term humoral immune response to Nipah virus in survivors 25 years after infection.
Do survivors of Nipah virus infection retain detectable antibodies and memory B cells 25 years post-infection?
Cohort (n=25)
Do survivors of Nipah virus infection retain detectable antibodies and memory B cells 25 years post-infection?
Nipah virus survivors retain detectable neutralizing antibodies and memory B cells 25 years after infection, highlighting long-lasting immune memory.
Detectable NiV antibodies and memory B cells persist 25 years post-infection; extends evidence of durable humoral immunity but leaves open correlates of protection.
OBJECTIVE: To evaluate the long-term humoral immune response to Nipah virus (NiV) in a cohort of 25 survivors after 25 years of post-infection. METHODS: A total of 25 survivors of NiV infection from the 1998 outbreak were recruited for sample collection. The serum IgG antibody response to NiV antigens, specifically nucleocapsid (N), fusion glycoprotein (F) and attachment glycoprotein (G) was evaluated using ELISA. Additionally, the samples were tested for neutralizing antibodies and memory B cell responses. RESULTS: Detection rates of anti-NiV-F and anti-NiV-G were 56% and 60%, respectively, among the survivors at a 1:100 dilution, whereas only 20% were specifically reactive to rNiV-N. Notably, all samples that tested positive for NiV-F and NiV-G at this dilution also exhibited neutralizing antibodies, highlighting the specificity of these assays. Live virus neutralization assay showed that 72% of survivors had detectable neutralizing antibodies, with varying titers, indicating long-lasting immune memory. Furthermore, memory B cell responses specific to NiV-F and NiV-G were observed in six randomly selected survivors, suggesting the presence of enduring immunological memory. CONCLUSIONS: These findings highlight the potential of NiV-F and NiV-G as reliable markers for NiV exposure and underscore the need for continuous surveillance and research. Such efforts are crucial for advancing vaccine development and improving preparedness for future NiV outbreaks.
No takes yet. Share an insight, caveat, or question.
Ong et al. (2025) conducted a cohort in Nipah virus (NiV) infection (n=25). Nipah virus infection was evaluated on Detectable neutralizing antibodies. After 25 years, 72% of Nipah virus survivors from the 1998 Malaysia outbreak retained detectable neutralizing antibodies and demonstrated memory B cell responses.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: